Research programme: inflammatory bowel disease therapy - BioLineRxAlternative Names: BL-1030
Latest Information Update: 09 May 2007
At a glance
- Originator Rimonyx Pharmaceuticals
- Class Small molecules
- Mechanism of Action L-selectin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 19 Jan 2005 Preclinical trials in Inflammatory bowel disease in Israel (unspecified route)